Everads Therapy, an ophthalmology-focused biotechnology company, entered into a license, collaboration and supply agreement with Kriya Therapeutics, Inc., to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ suprachoroidal delivery platform that enables non-surgical delivery to the back of the eye via the suprachoroidal space. The agreement follows a research collaboration between the parties whereby Everads’ platform was evaluated for delivery of ...